Literature DB >> 1555279

Metabolic responses of hibernating and infarcted myocardium to revascularization. A follow-up study of regional perfusion, function, and metabolism.

T H Marwick1, W J MacIntyre, A Lafont, J J Nemec, E E Salcedo.   

Abstract

BACKGROUND: The presence of persistent myocardial uptake of 18F-deoxyglucose (FDG) within hypoperfused, dysfunctional segments has been shown to predict the recovery of regional contractile function after revascularization. The spectrum of metabolic responses of such hibernating tissue to revascularization is less clear. METHODS AND
RESULTS: Sixteen patients with previous infarction were studied before and after revascularization by myocardial perfusion imaging using 82Rb positron emission tomography, digitized two-dimensional echocardiography, and imaging of postexercise FDG uptake. Hibernation was identified in 35 of 85 segments showing perfusion and wall motion disturbances before intervention. At follow-up (4.9 +/- 2.6 months after revascularization), hibernating segments were characterized by reduction of wall motion score (p less than 0.001), improvement of perfusion (p less than 0.001), and reduction of FDG activity (p less than 0.001). Of the 35 hibernating segments, however, 10 still had abnormal elevation of FDG uptake (greater than 2 SD above normal) without differing from other hibernating segments with respect to postoperative perfusion or wall motion score. Segments with persistently abnormal metabolism were characterized before intervention by more severe malperfusion (p less than 0.01) and greater FDG activity (p less than 0.01).
CONCLUSIONS: Although wall motion and perfusion improve with revascularization of hibernating tissue, myocardial metabolism remains abnormal in a significant proportion of segments. These segments are characterized by more extensive perfusion and metabolic changes before revascularization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1555279     DOI: 10.1161/01.cir.85.4.1347

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

Review 1.  BMIPP in angina pectoris.

Authors:  S Nishimura; Y Ohta
Journal:  Int J Card Imaging       Date:  1999-02

Review 2.  Radionuclide techniques for the assessment of myocardial viability.

Authors:  E Skoufis; A I McGhie
Journal:  Tex Heart Inst J       Date:  1998

Review 3.  Myocardial hibernation and stunning: from physiological principles to clinical practice.

Authors:  S R Redwood; R Ferrari; M S Marber
Journal:  Heart       Date:  1998-09       Impact factor: 5.994

Review 4.  Molecular and cellular basis of viable dysfunctional myocardium.

Authors:  Marina Bayeva; Konrad Teodor Sawicki; Javed Butler; Mihai Gheorghiade; Hossein Ardehali
Journal:  Circ Heart Fail       Date:  2014-07       Impact factor: 8.790

Review 5.  [Examination of myocardial perfusion with positron emission tomography: a clinically useful and valid method?].

Authors:  J vom Dahl
Journal:  Herz       Date:  1997-02       Impact factor: 1.443

Review 6.  Myocardial hibernation in terms of the flow-function relationship.

Authors:  K P Gallagher
Journal:  Basic Res Cardiol       Date:  1995 Jan-Feb       Impact factor: 17.165

Review 7.  Assessment of viability after myocardial infarction. Clinical relevance and methodological problems.

Authors:  G Fragasso; A Margonato; S L Chierchia
Journal:  Int J Card Imaging       Date:  1993

Review 8.  Chronic ischemic left ventricular dysfunction: from pathophysiology to imaging and its integration into clinical practice.

Authors:  Shahbudin H Rahimtoola; Vasken Dilsizian; Christopher M Kramer; Thomas H Marwick; Jean-Louis J Vanoverschelde
Journal:  JACC Cardiovasc Imaging       Date:  2008-07

Review 9.  Myocardial viability: what do we need?

Authors:  H Schoeder; M Friedrich; H Topp
Journal:  Eur J Nucl Med       Date:  1993-09

Review 10.  Noninvasive assessment myocardial viability: current status and future directions.

Authors:  Kevin C Allman
Journal:  J Nucl Cardiol       Date:  2013-06-15       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.